GGrantIndex
Sort

40,608 grants matching prostate cancer

Project 3: Analysis of intrinsic and extrinsic factors that promote prostate neuroendocrine differentiation

$639,074
Michael M. Shen · Columbia University Health Sciences · P01 · FY2022 · CA

ProstaFluor FDA Trial for Real-Time Margin Detection During Prostatectomy

$639,000
David A. Benaron · Spectros Corporation · R01 · FY2010 · CA

HUMAN MUC1 ONCOPTOTEIN IS OF FUNCATIONAL IMPORTANCE TO THE DEVELOPMENT OF PROSTATE CANCER

$638,998
Dana-Farber Cancer Institute, Inc. · · FY2008 · Department of the Army

HRQoL Values for Cancer Survivors: Enhancing PROMIS Measures for CER

$638,811
Benjamin M Craig · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2014 · CA

PLASMA ANGIOME AND SERUM ANDROGENS AS PREDICTORS OF OVERALL SURVIVAL IN METASTATIC PROSTATE CANCER

$638,787
Duke University · · FY2018 · Defense Health Agency

Blood-Based Biomarkers for Personalized Risk Assessment of Breast and Ovarian Cancer

$638,683
Johannes F Fahrmann · University Of Tx Md Anderson Can Ctr · U01 · FY2024 · CA

Use of Circulating MicroRNAs for Early Detection and Risk Assessment for Pancreatic Cancer

$638,665
Xiao-Ou Shu · Vanderbilt University Medical Center · R01 · FY2020 · CA

Application of MAGNet Tools to Gene Regulatory Networks in Cancer

$638,491
Chris Sander · Sloan-Kettering Inst Can Research · R01 · FY2008 · CA

Cell free nucleic acid-based biomarkers in advanced prostate cancer

$638,405
Liang Wang · Medical College Of Wisconsin · R01 · FY2018 · CA

Chip-Scale Intraoperative Optical Navigation with Immunotargeted Upconverting Nanoparticles

$638,388
Mekhail Anwar · University Of California, San Francisco · R01 · FY2025 · CA

Culturally Adapted Cognitive Behavioral Stress and Self-Management (C-CBSM) Intervention for PC

$638,319
Frank J Penedo · Northwestern University At Chicago · R01 · FY2017 · CA

Pelvic fascia spARing radical prostatectomy TrIAL (PARTIAL)

$638,257
Jim Hu · Weill Medical Coll Of Cornell Univ · R01 · FY2025 · CA

MELT: Modulation of PSMA Expression for Lutetium Therapy

$638,248
Thomas Hope · University Of California, San Francisco · R01 · FY2022 · CA

Identifying lethal prostate cancer at diagnosis with advanced proteoglycomic, radiomic, and genomic approaches

$637,936
Joseph Edward Ippolito · Washington University · R01 · FY2023 · CA

Preventing Falls and Frailty in Prostate Cancer Survivors: GET FIT Prostate

$637,906
Kerri M Winters-Stone · Oregon Health & Science University · R01 · FY2021 · CA

PROMISS - Prostate Modeling to Identify Surveillance Strategies

$637,795
Ruth D Etzioni · Fred Hutchinson Cancer Research Center · R01 · FY2013 · CA

Genetic determinants of gene expression phenotypes in aggressive prostate cancer

$637,767
Liang Wang · Medical College Of Wisconsin · R01 · FY2011 · CA

Multiscale Modeling of Bone Environment Responses to Metastatic Prostate Cancer

$637,735
David Basanta Gutierrez · H. Lee Moffitt Cancer Ctr & Res Inst · U01 · FY2020 · CA

PSMA-PET to Guide Prostatectomy: Can PSMA-PET Appropriately Modify Surgery, Reduce Nerve Damage and Optimize Quality-of-Life?

$637,698
Clinton David Bahler · Indiana University Indianapolis · R01 · FY2022 · CA

Phase III Trial of Selenium for Prostate Cancer Prevention

$637,649
University Of Arizona · R01 · FY2005 · CA

Targeting Neuroendocrine Prostate Cancer Using Multi-Probe Hyperpolarized 13C MRI for Improved Treatment and Therapeutic Monitoring

$637,566
John Kurhanewicz · University Of California, San Francisco · R01 · FY2019 · CA

Genetics Variants in the Genome Predisposing to Aggressive PCa

$637,540
William B Isaacs · Johns Hopkins University · R01 · FY2009 · CA

CHOLESTEROL PROMOTES REPROGRAMMING OF PROSTATE CANCER PROGRESSION AND METASTASIS

$637,501
Cedars-Sinai Medical Center · · FY2018 · Department of the Army

PRECLINICAL ASSESSMENT OF BMX/ETK INHIBITORS FOR PROSTATE CANCER

$637,500
Beth Israel Deaconess Medical Center, Inc. · · FY2009 · Department of the Army

IDENTIFICATION AND TARGETING OF UPSTREAM TYROSINE KINASES MEDIATING P13 KINASE ACTIVATION IN PTEN-DEFICIENT PROSTATE CANCER

$637,500
Beth Israel Deaconess Medical Center, Inc. · · FY2008 · Department of the Army